BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28786806)

  • 1. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
    Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
    J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPSTEIN-BARR VIRUS AND NASOPHARYNGEAL CARCINOMA: VIRAL MARKERS FOR DIAGNOSTICS AND ASSESSMENT OF CLINICAL STATUS OF PATIENTS.
    Kondratova VN; Lomaya MV; Ignatova AV; Dushenkina TE; Smirnova KV; Mudunov AM; Lichtenstein AV; Gurtsevitch VE; Senyuta NB
    Vopr Virusol; 2018 Apr; 63(2):77-84. PubMed ID: 36494925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
    Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
    Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma.
    Coghill AE; Wang CP; Verkuijilen SAWM; Yu KJ; Hsu WL; Middeldorp JM; Hildesheim A
    J Med Virol; 2018 Jan; 90(1):191-195. PubMed ID: 28833336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.